Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Nov 24, 2023 Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award Oct 31, 2023 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement Oct 26, 2023 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement Oct 25, 2023 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement Oct 24, 2023 Theratechnologies Announces Operational Update Oct 19, 2023 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV Oct 16, 2023 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon Oct 13, 2023 Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs) Oct 13, 2023 Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study Oct 12, 2023 Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 41 - 50 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Oct 31, 2023 Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Oct 26, 2023 Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
Oct 25, 2023 Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
Oct 19, 2023 Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Oct 16, 2023 Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
Oct 13, 2023 Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Oct 13, 2023 Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
Oct 12, 2023 Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
